Phocas Financial Corp. Supernus Pharmaceuticals, Inc. Transaction History
Phocas Financial Corp.
- $134 Billion
- Q4 2024
A detailed history of Phocas Financial Corp. transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Phocas Financial Corp. holds 16,407 shares of SUPN stock, worth $536,180. This represents 0.44% of its overall portfolio holdings.
Number of Shares
16,407
Previous 109,460
85.01%
Holding current value
$536,180
Previous $3.41 Million
17282.86%
% of portfolio
0.44%
Previous 0.01%
Shares
11 transactions
Others Institutions Holding SUPN
# of Institutions
303Shares Held
60.6MCall Options Held
22.3KPut Options Held
6K-
Black Rock Inc. New York, NY10.4MShares$340 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.15MShares$201 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY4.84MShares$158 Million2.47% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.88MShares$94.1 Million0.03% of portfolio
-
Macquarie Group LTD Australia, C32.63MShares$85.9 Million0.11% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $1.75B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...